Short Wave Brain Scientists Are Tripping Out Over Psychedelics
Dec 21, 2022
Jon Hamilton, NPR's brain correspondent and an expert in neuroscience, joins the conversation about the resurgence of interest in psychedelics like MDMA and psilocybin. They delve into the therapeutic potential of these substances for treating mental health disorders such as depression and PTSD. The discussion also highlights the importance of navigating both the promises and perils of psychedelic treatments. Hamilton emphasizes the need for realistic expectations, comprehensive clinical oversight, and the growing involvement of companies in the psychedelic industry.
AI Snips
Chapters
Transcript
Episode notes
Psychedelics Research Resurgence
- Renewed interest in psychedelics started in the 1990s.
- Two 2016 studies on psilocybin showed reduced depression and anxiety in cancer patients, marking a turning point.
Crowded Neuroscience Session
- Jon Hamilton attended a session on psychedelics and neuroplasticity, which was extremely crowded.
- This highlighted the surging interest in psychedelic research.
Psilocybin and Brain Plasticity
- Psilocybin strengthens dendrite connections, leading to increased brain plasticity in mice.
- This enhanced plasticity may enable the brain to rewire and potentially treat conditions like depression.